Disclaimer and Regulatory Information

Forward Looking Statements

All statements and expressions are the sole opinion of the editor and are subject to change without notice.  The Company is not liable for any investment decisions by its readers or subscribers.  It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies.  The information contained herein has been provided as an information service only.  The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained.  Investors are cautioned that they may lose all or a portion of their investment in this or any other company.

Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements".  Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.

These and other risks are described in our most recent disclosure documents filed with the Securities and Exchange Commission. Our SEC filings are available to the public at the SEC's website at: http://www.sec.gov.

Antimicrobial Efficacy Data and U.S. Regulatory Status

This website includes microbiology data to assist in technology evaluation.  Data presented herein were collected using standard laboratory methods and are presented solely to substantiate the efficacy of Quick-Med’s antimicrobial technologies.  Display of this data is not intended to be a public health claim.  

NIMBUS® technology received FDA market clearance for use in a wound dressing in February, 2009. 

Stay Fresh technology is registered with EPA (EPA Reg. # 87358-1) as an antimicrobial textile finish.  Consumer goods that are prepared in accordance with the EPA registration are regulated under the Treated Articles exemption of FIFRA, and EPA provides guidance on permitted claims for these products.  No public health claims are permissible, and the antimicrobial is intended to protect the treated article itself. 

Stay Fresh™ received clearance from FDA in May 2013, for an antibacterial medical textile (K121898), specifically for use in managing skinfolds.  This product is not yet in U.S. commerce. 

NimbuDerm™ technology is neither FDA-cleared nor EPA-registered at this time, and is not currently commercialized in the U.S.